Rafferty Asset Management LLC Grows Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Rafferty Asset Management LLC grew its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 3.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 178,165 shares of the company’s stock after buying an additional 6,643 shares during the quarter. Rafferty Asset Management LLC’s holdings in Syndax Pharmaceuticals were worth $2,355,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in SNDX. Barclays PLC boosted its stake in shares of Syndax Pharmaceuticals by 143.4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company’s stock valued at $3,612,000 after purchasing an additional 110,535 shares in the last quarter. Inspire Investing LLC boosted its stake in shares of Syndax Pharmaceuticals by 44.5% in the 4th quarter. Inspire Investing LLC now owns 30,792 shares of the company’s stock valued at $407,000 after purchasing an additional 9,484 shares in the last quarter. KBC Group NV boosted its stake in shares of Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company’s stock valued at $92,000 after purchasing an additional 3,559 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Syndax Pharmaceuticals in the 4th quarter valued at $26,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Syndax Pharmaceuticals by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company’s stock valued at $239,000 after purchasing an additional 1,732 shares in the last quarter.

Syndax Pharmaceuticals Trading Up 2.8%

Shares of NASDAQ SNDX opened at $9.30 on Tuesday. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $25.07. The firm has a market capitalization of $800.24 million, a PE ratio of -2.56 and a beta of 0.82. The firm has a fifty day simple moving average of $12.02 and a two-hundred day simple moving average of $13.97.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.06. The company had revenue of $20.04 million during the quarter, compared to the consensus estimate of $15.88 million. During the same quarter last year, the company posted ($0.85) earnings per share. The firm’s revenue for the quarter was up 1900.0% compared to the same quarter last year. On average, sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SNDX. Guggenheim reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. HC Wainwright reiterated a “buy” rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a report on Tuesday, May 6th. Scotiabank upped their price target on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a “sector perform” rating in a report on Tuesday, May 6th. Finally, Citigroup lowered their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $35.91.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).